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Abstract
OBJECTIVE—To estimate time trends of actual provider use of human papillomavirus (HPV) 
testing in cervical cancer screening by using laboratory and administrative data from the Johns 
Hopkins Hospital Division of Cytopathology in Baltimore, Maryland.
METHODS—In this ecologic trend study, we analyzed 178,510 Pap specimen records and 12,221 
HPV tests among 85,048 patients from 2001 to 2007. Monthly frequencies and proportions of 
HPV reflex testing and HPV cotesting with Pap (stratified by patient ages 30 and older and 18–29 
years) were calculated. Time trends of monthly HPV testing proportions were analyzed using 
joinpoint regression methods.
RESULTS—From April 2002, when the American Society for Colposcopy and Cervical 
Pathology added HPV reflex testing to its guidelines, to December 2007, the monthly the 
proportion of reflex testing was 95.8%. From February 2004, when the society added HPV 
cotesting with Pap among women aged 30 years or older to its guidelines, to December 2007, the 
overall proportion HPV cotesting with Pap among patients aged 30 years or older was 7.8% 
(compared with 4.9% among patients 18–29 years [P<.01]). The highest proportion of HPV 
cotesting among women aged 30 years or older, 15%, was observed in September 2006, and the 
trend later plateaued around 13%. The monthly proportions of HPV reflex testing and cotesting 
with Pap changed significantly over time.
CONCLUSION—These data reveal that a small percentage of women aged 30 years or older 
received HPV cotesting with Pap, thus identifying a significant opportunity for providers to 
improve patient care in cervical cancer prevention.
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The high-risk human papillomavirus (HPV) test is approved by the U.S. Food and Drug 
Administration (FDA) for follow-up of a specific abnormal Pap diagnosis, atypical 
squamous cells of undetermined significance (ASC-US) (ie, reflex testing) and for HPV 
cotesting with Pap among women 30 years or older (ie, cotesting) during routine cervical 
cancer screening.1 The importance and value of HPV cotesting is reflected by its inclusion 
in screening guidelines of the American Society for Colposcopy and Cervical Pathology 
(ASCCP), the American Cancer Society, and other organizations.2-5
Although HPV testing plays an increasingly important role in cervical cancer prevention, 
little information about actual provider use of the HPV test is documented in the scientific 
literature. The few studies to consider this topic6 are based primarily on provider self-report 
and case vignettes, rather than on actual provider practice data. Provider surveys suggest 
there is non–evidence-based use of HPV testing,7-10 and marketing and media coverage of 
the HPV test and HPV vaccine has been prevalent in the public and medical 
communities.11,12 Rapid changes in prevention, such as FDA approval of the HPV 
vaccine,13 in addition to media and advertising attention, may exacerbate confusion over 
screening recommendations.9,14
The purpose of this ecologic study was to estimate time trends of high-risk HPV testing for 
two FDA-approved uses: 1) HPV reflex testing of ASC-US Pap results and 2) HPV 
cotesting with Pap among women 30 years or older during cervical cancer screening. We 
used 7 years of Pap specimen data from the Johns Hopkins Hospital Division of 
Cytopathology in Baltimore, Maryland.
MATERIALS AND METHODS
Data originated from the Pathology Data System, an in-house, comprehensive laboratory 
information system administratively maintained by the Johns Hopkins Hospital Department 
of Pathology. The Pathology Data System contains individual specimen record information 
and associated test results, diagnoses, and provider and patient information for all specimens 
submitted by inpatient units, outpatient clinics, and outside accounts to the Department of 
Pathology for processing and evaluation. In this ecologic trend study, we used a subset of 
the Pathology Data System data that included all Pap specimens processed by the Johns 
Hopkins Hospital Division of Cytopathology and HPV tests processed by the hospital’s 
Division of Microbiology. A statistical programmer de-identified the Pathology Data System 
data to create a limited data set for the analysis. Before commencement of this research, the 
Johns Hopkins Bloomberg School of Public Health Institutional Review Board determined 
the study to be exempt human subjects research and, thus, the requirement to obtain 
informed consent was waived.
The limited data set contained all Pap specimens processed by the Johns Hopkins Hospital 
Division of Cytopathology from January 1, 2001, to December 31, 2007, (N=195,981). 
Variables included new unique specimen identifier, new unique patient identifier, date the 
Pap specimen was taken, Pap diagnosis, clinic ordering the Pap, patient age, patient sex, 
patient home ZIP code, patient race, patient insurance type, and HPV result, if such a test 
was completed. The continuous variable of patient age was categorized according to decade. 
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Categorical variables of patient race, insurance, and home ZIP code were collapsed 
according to their distribution and relevance to the study design and setting. SQL 
programming in Access 2007 was used to extract pertinent information (ie, type of Pap 
[conventional versus liquid-based], Pap result, possible HPV test and result) from the “free 
text” Pap diagnosis variable. Pap diagnoses were categorized as “negative for intraepithelial 
lesion or malignancy (normal),” “atypical squamous cells of undetermined significance 
(ASC-US),” “low-grade squamous intraepithelial lesion (LSIL),” “high-grade squamous 
intraepithelial lesion (HSIL),” “atypical glandular cells of undetermined significance 
(AGUS),” “carcinoma (cancer),” “specimen unsatisfactory/discarded,” and “cannot be 
classified.” Pap results that indicated two possible diagnoses in a single record were 
classified according to the more severe diagnosis. At the time of this study, the digene HPV 
test (QIAGEN, formally Digene Corporation), which detects the DNA of 13 oncogenic HPV 
types in a cervical specimen,1 was the only FDA-approved high-risk HPV test in the United 
States. HPV test results were categorized as “negative,” “positive,” and “equivocal.” The 
Johns Hopkins Hospital Division of Microbiology defined negative HPV results as less than 
0.85 relative light units, equivocal HPV results as 0.85 to 3.0 relative light units, and 
positive HPV results as more than 3.0 relative light units.
For the present analysis, we excluded records missing data on patient age, patient sex, type 
of Pap test, or final diagnosis (n=182). Because our focus was routine cervical cancer 
screening among adults, we excluded records from patients younger than 18 years old 
(n=7,130). We also excluded specimens collected before January 1, 2001 (n=113) and from 
clinics that contributed Pap specimens on only 1 day in the 7-year study period (n=82). We 
excluded specimens that were unsatisfactory or discarded or both, and those with diagnoses 
that could not be classified based on information in the “free text” Pap diagnosis variable 
(n=1,823). Finally, because our aim was to estimate trends of HPV testing in routine cervical 
cancer screening, we excluded specimens from clinics that focus on non-adult screening (eg, 
adolescent clinics; n=1,412), referral clinics (eg. colposcopy, oncology; n=3,258), and 
human immunodeficiency virus (HIV) clinics (n=3,471). The final analytic data set 
contained 178,510 Pap specimen records (91.1% of total data) among 85,048 unique patients 
in 216 clinics in the Baltimore, Maryland, metropolitan area. The unique clinics originated 
from inpatient units of multiple Johns Hopkins hospitals, outpatient facilities affiliated with 
Johns Hopkins, and outpatient facilities not affiliated with Johns Hopkins, including several 
federally qualified health centers. The 216 clinics were heterogeneous according to setting, 
size of patient populations, number of providers, and so on.
Using Pap specimen as the unit, we calculated the monthly frequencies of liquid-based Pap, 
conventional Pap, and HPV testing. Frequencies of the two FDA-approved uses of the HPV 
test were our primary outcomes: HPV reflex testing and HPV cotesting with Pap among 
women 30 years or older. We limited our analysis of HPV testing to liquid-based Pap 
specimen records because the general use of the cocollection of conventional Pap and digene 
specimen transport medium was unknown.
HPV reflex testing was defined as use of the testing for a Pap specimen diagnosed as ASC-
US regardless of the patient’s age. HPV cotesting with Pap was defined as use of the testing 
for a Pap specimen with a non–ASC-US diagnosis (ie, negative for intraepithelial lesion or 
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malignancy [normal], LSIL, HSIL, or carcinoma [cancer]) for a patient aged 30 years or 
older. HPV cotesting with Pap among patients aged younger than 30 years is not an FDA-
approved use of the HPV test. We excluded Pap diagnoses of atypical glandular cells of 
undetermined significance because the Johns Hopkins Hospital Division of Cytopathology 
occasionally ordered HPV testing for these diagnoses regardless of provider instructions.
We calculated the overall proportion of HPV reflex testing by dividing the total number of 
HPV tests conducted on liquid-based Pap specimens with an ASC-US diagnosis by the total 
number of liquid-based Pap specimens with an ASC-US diagnosis from April 2002, when 
the ASCCP added HPV reflex testing to its screening guidelines,15 to December 2007. For 
HPV cotesting with Pap, we calculated the overall proportion by dividing the total number 
of HPV tests conducted on liquid-based Pap specimens with a non–ASC-US diagnosis (ie, 
normal, LSIL, HSIL, cancer, and not atypical glandular cells of undetermined significance) 
by the total number of liquid-based Pap specimens with a non–ASC-US diagnosis. This 
calculation focused on the time between February 2004, when the ASCCP added HPV 
cotesting with Pap for women 30 years or older to its guidelines,3 and December 2007. 
Because HPV cotesting with Pap is suggested for women 30 years or older, we calculated 
the proportions of cotesting with Pap in strata of patient age 18–29 years and 30 years or 
older. We estimated the proportions of reflex testing and cotesting with Pap in categories 
defined by the covariates and tested for differences using Pearson χ2. Results were 
considered statistically significant if P≤.05.
To conduct quantitative ecologic time trend analyses, we employed joinpoint regression 
modeling, which identifies statistically significant changes (eg, “joinpoints”) in linear slope 
trends over time.16 Using the Joinpoint Regression Program 3.4.3, we fit the simplest 
joinpoint model to the HPV monthly proportions data. Briefly, the software begins with 0 
joinpoints (ie, a straight line) and statistically tests whether adding more joinpoints (up to a 
total of 4) will more appropriately fit the data. Monte Carlo Permutation methods are used 
for tests of significance. We specified a log-linear model assuming a Poisson distribution to 
allow for calculating monthly percent change of regression line segments between 
joinpoints. The monthly percent change is calculated by fitting a linear regression to the 
natural log of the monthly HPV testing proportions with calendar month as the regressor. 
The coefficient from this regression is the slope (m) of the change in HPV testing 
proportions over calendar month, and the monthly percent change is calculated as: monthly 
percent change=100×(em−1).17 Monthly percent change estimates were reported with 95% 
confidence intervals. Unless otherwise noted, all data management and analysis were 
conducted using Stata/SE Version 11.
RESULTS
The analytic data set included 178,510 Pap specimen records; 133,938 (75.0%) were liquid-
based Pap tests and 44,572 (25.0%) were conventional Pap tests, and 12,221 HPV tests were 
processed. The specimen records originated from 85,048 unique women. The number of 
Paps per unique woman ranged from 1 to 17 with a median of 1 and a mean of 2.1 (standard 
deviation 1.6). Sixty-eight and six-tenths percent of the study population was age 30 years or 
older. The study population was predominately white or black (42.6% and 36.2%, 
Phelan et al. Page 4









respectively), and the majority of patients (53.7%) had Baltimore City home ZIP codes. 
There was a wide range of insurance types (Table 1).
From April 2002, when the ASCCP added HPV reflex testing to its screening guidelines,15 
to December 2007, the proportion of reflex testing was 95.8% (n=5,370). From February 
2004, when the ASCCP added HPV cotesting with Pap for women 30 years or older to its 
guidelines,3 to December 2007, the proportion of cotesting with Pap among patients aged 30 
years or older was 7.8% (n=4,588). In the same timeframe, the proportion of non–
evidenced-based HPV cotesting with Pap among patients 18–29 years was 4.9% (n=1,158; 
P<.01). Cotesting with Pap differed by patient age category (P<.01). We graphed the 
monthly frequencies of HPV testing, conventional Pap testing, and liquid-based Pap testing. 
Liquid-based Pap testing increased over the 7-year study period from 769 to 1,866 tests per 
month. Conventional testing decreased from 1,931 to 0 tests per month. The monthly 
frequency of HPV testing gradually increased from 4 to 280 tests per month with a notable 
rise in mid-2005 (Fig. 1).
We next plotted the monthly proportions of HPV reflex testing and HPV cotesting with Pap 
(stratified by patient ages 18–29 years and 30 years or older). The proportion of reflex 
testing increased during the study time period from 0% to nearly 100% (Fig. 2). The 
variation in reflex testing before 2003 may be related to the changing frequencies of 
conventional and liquid-based Pap tests, as HPV reflex testing was generally performed only 
on liquid-based Pap specimens through the Johns Hopkins Hospital Division of 
Cytopathology. For HPV cotesting with Pap, testing was slightly more frequent among 
patients aged 18–29 years, which was non–evidence-based use, than among patients 30 
years or older from 2001 to mid-2005. In mid- to late-2005, the proportion of cotesting 
among patients 30 years or older notably increased nearly 5-fold from to 2.2% to 10.7%. 
The highest proportion, 15%, was observed in September 2006, and the trend later plateaued 
around 13% (Fig. 2).
To more quantitatively estimate trends of HPV testing over time, we fit joinpoint regression 
models to the monthly proportion data. We identified points of statistically significant 
change in temporal linear trends and we calculated monthly percent change for HPV reflex 
testing and for HPV cotesting with Pap stratified by age. For reflex testing, three trends of 
monthly percent change were identified: −1.1% for January 2001 to December 2001, 13.2% 
for December 2001 to May 2002, and 0.1% for May 2002 to December 2007 (Table 2). The 
monthly percent change estimate between December 2001 and May 2002, 13.2% (95% 
confidence interval 1.4%–26.5%), reflected a significant change in trend as the estimate was 
statistically significant from 0 (ie, statistically significant from 0 monthly percent change).
For evidence-based HPV cotesting with Pap among patients 30 years or older, four trends of 
monthly percent change were identified: 6.6% for January 2001 to February 2002, −0.8% 
for February 2002 to July 2005, 66.9% for July 2005 to November 2005, and 1.0% for 
November 2005 to December 2007. Three of these trends were statistically significant. For 
non–evidence-based HPV cotesting with Pap among patients younger than 30 years, there 
were also four trends of monthly percent change: 1.0% for January 2001 to December 2004, 
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−18.1% for December 2004 to May 2005, 9.0% for May 2005 to July 2006, and 0.2% for 
July 2006 to December 2007. Two of these trends were statistically significant (Table 2).
DISCUSSION
Using laboratory and administrative data, we estimated actual provider use of the HPV test 
for two FDA-approved indications: 1) HPV reflex testing for ASC-US Pap results and 2) 
HPV cotesting with Pap among women 30 years or older in the Baltimore metropolitan area. 
HPV reflex testing of ASC-US Pap results is considered the standard of care in cervical 
cancer prevention in the United States, and the proportion of reflex testing increased to 
nearly 100% during the study period. A survey of 679 cytology laboratories in the United 
States found that 89.8% of laboratories offered HPV testing for reflex of ASC-US Pap test 
results.18
Our findings reveal that a small proportion (ie, 15% at most) of women 30 years or older 
received HPV testing with their Pap test for cervical cancer screening, despite HPV 
cotesting with Pap for this patient population being recommended since 2004 by three 
prominent professional organizations (reviewed in Wright et al3) and reimbursed by many 
insurance companies.19 This represents a significant gap in prevention practices and patient 
care. Although HPV cotesting with Pap is available through the Johns Hopkins Hospital 
Division of Cytopathology, Moriarty et al reported that only 24.5% of a sample of cytology 
laboratories offered non–reflex HPV testing for screening for women 30 years or older, and 
59.3% offered non–reflex HPV testing for any reason.18 These data also reveal women aged 
18–29 years received cotesting with Pap screening, even though the test is not FDA-
approved for cotesting use among women younger than 30 years.1 Analogous relationships 
of “off-label” use have been observed in surveys of providers8,9 and cytology laboratories.18
We considered the study’s findings in the context of developments in cervical cancer 
prevention (Fig. 3): ASCCP guidelines began to include HPV cotesting for women 30 years 
or older (February 2004), consumer marketing of the test in the Baltimore, Maryland 
(March–May 2005) and Washington, DC (April–June 2006) metropolitan areas, and FDA 
approval of the first HPV vaccine (June 2006). It is intriguing that the increase in 2005 takes 
place shortly after the HPV test marketing campaign in the Baltimore metropolitan area, 
although we can in no way establish causality. Patient request for the HPV test and provider 
misuse of the test may be related to marketing aimed at providers and patients9 and to media 
coverage of the HPV vaccine and cervical cancer prevention.14 It would be elucidating to 
characterize the relative effect of updated guidelines compared with consumer and provider 
marketing.
A large strength of this study was its unique data source, which contained data on actual 
provider practices (compared with self-report practices). A similar provider practice analysis 
was recently reported using Florida Medicaid administrative claims data.10 This study also 
showed an increase in usage of HPV DNA tests from 0.6% in July 2001 to 9.0% in June 
2009. Other strengths of this work include its contiguous 7-year study period and that all 
data are from one cytology laboratory. The 178,510 Pap specimens analyzed were from 
85,048 unique women in more than 200 unique clinics. In contrast to the Florida Medicaid 
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study, there was a large amount of heterogeneity among the patients by age, race, and 
insurance type. Further, we were able to document time trends of HPV testing stratified by 
reflex and cotesting indication.
The analysis is not without limitations. The Pathology Data System is not a gold standard of 
provider practice data and we lacked information such as patient test request, screening 
history, and time when insurance companies began reimbursement for HPV cotesting. We 
also captured data only from Pap specimens sent to the Johns Hopkins Hospital Division of 
Cytopathology for evaluation. If a patient’s insurance company required the specimen be 
sent to Quest Diagnostics or LabCorp, we had no opportunity to capture the Pap or HPV test 
results or both. As such, we had no way to quantify the direction or magnitude of this 
selection bias, nor could we evaluate whether screening practices varied by cytology 
laboratory or insurance company. Whereas it is helpful to consider the role of extrinsic 
factors, such as marketing, on HPV test use, we cannot assume causality in time trends. 
Given the academic setting of Johns Hopkins and that HPV cotesting is not available in all 
cytology laboratories,18 the findings of this study may not be generalizable to other 
organizations and settings.
This study identifies a significant opportunity for improving preventive care and allows 
providers to compare their own practices with those reported here. The findings of this study 
suggest there may be barriers to adoption of HPV cotesting with Pap among women 30 
years or older. More research is needed to fully characterize use of HPV testing, including 
system-, provider-, and patient-level factors that may affect screening practices and 
preferences, such as provider sex6,9 and patient race or ethnicity.20
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Monthly frequencies of human papillomavirus (HPV) testing, conventional Pap testing, and 
liquid-based Pap testing among Pap specimens processed by the Johns Hopkins Hospital 
Division of Cytopathology, 2001–2007.
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Monthly proportions of human papillomavirus (HPV) reflex testing and cotesting with Pap 
for Pap specimens processed by the Johns Hopkins Hospital Division of Cytopathology, 
2001–2007.
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Monthly proportions of human papillomavirus (HPV) cotesting with Pap (stratified by 
patient age) for Pap specimens processed by the Johns Hopkins Hospital Division of 
Cytopathology, shown with key dates in cervical cancer prevention in the Baltimore, 
Maryland, metropolitan area, 2001–2007.
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Table 1
Study Population Characteristics (n=85,048)
Characteristic n (%)
Age category (y)
 18–20 7,228 (8.5)
 21–29 19,476 (22.9)
 30–39 18,064 (21.2)
 40–49 15,811 (18.6)
 50–59 11,669 (13.7)
 60–69 7,059 (8.3)
 70 or older 5,741 (6.8)
Race
 White 36,234 (42.6)
 Black 30,746 (36.2)
 Asian 2,109 (2.5)
 Hispanic 1,417 (1.7)
 Other 6,043 (7.1)
 Missing 8,499 (10.0)
Insurance type
 Preferred provider organization 19,650 (23.1)
 Blue Shield 10,803 (12.7)
 Medicaid 10,031 (11.8)
 Medicare 8,200 (9.6)
 Military 5,999 (7.1)
 Health maintenance organization 4,116 (4.8)
 Other 2,068 (2.4)
 Self-pay 172 (0.2)
 Type unknown 9,596 (11.3)
 Missing 14,413 (17.0)
Home ZIP code
 Baltimore City 45,632 (53.7)
 Other Maryland 19,417 (22.8)
 Non-Maryland 3,676 (4.3)
 Missing 16,323 (19.2)









Phelan et al. Page 13
Table 2
Type of Human Papillomavirus Testing and Associated Time Trends, Including Monthly 
Percent Change Estimates
Time Trend 1 Time Trend 2 Time Trend 3 Time Trend 4
HPV Testing Period MPC Period MPC Period MPC Period MPC
Reflex Jan 2001–
 Dec 2001
−1.1 (−4.5–2.5) Dec 2001–
 May 2002
13.2* (1.4–26.5) May 2002–
 Dec 2007
0.1 (0.0–0.2) N/A N/A
Cotesting 
with




6.6* (0.8–12.7) Feb 2002–
 July 2005
−0.8 (−1.8–0.1) July 2005–
 Nov 2005









1.0* (0.2–1.8) Dec 2004–
 May 2005
−18.1 (−44.2–20.4) May 2005–
 July 2006
9.0* (2.5–15.9) July 2006–
 Dec 2007
0.2 (−2.4–2.9)
HPV, human papillomavirus; MPC, monthly percent change; N/A, not applicable.
Data are % (95% confidence interval).
*
Monthly percent change is statistically significant from 0.
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